论文部分内容阅读
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of neoplasm with different clinical,immunophenotypic,and genetic abnormalities as well as highly variable prognosis.In this study,we analyzed Bcl-2 protein expression by immunohistochemistry (IHC) in 60 patients with de novo DLBCL treated with R-CHOP (rituximab,cyclophosphamide,doxorubicin,vincristine,and prednisone).